Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine

BACKGROUND: BCL‐2 inhibition through venetoclax (VEN) targets acute myeloid leukemia (AML) blast cells and leukemic stem cells (LSCs). Although VEN-containing regimens yield 60–70% clinical response rates, the vast majority of patients inevitably suffer disease relapse, likely because of the persist...

Descripción completa

Detalles Bibliográficos
Autores principales: Buettner, Ralf, Nguyen, Le Xuan Truong, Morales, Corey, Chen, Min-Hsuan, Wu, Xiwei, Chen, Lisa S., Hoang, Dinh Hoa, Hernandez Vargas, Servando, Pullarkat, Vinod, Gandhi, Varsha, Marcucci, Guido, Rosen, Steven T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074444/
https://www.ncbi.nlm.nih.gov/pubmed/33902674
http://dx.doi.org/10.1186/s13045-021-01076-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074444/
https://www.ncbi.nlm.nih.gov/pubmed/33902674
http://dx.doi.org/10.1186/s13045-021-01076-4

Ejemplares similares